2+ day, 13+ hour ago   (214+ words) Erica L. Mayer, MD, MPH, explained why oncologists should switch to camizestrant at ESR1 mutation emergence rather than reserve oral SERDs for progression. Aditya Bardia, MD, MPH, FASCO; Priya Kumar, MBBS, MS Aditya Bardia, MD, MPH, FASCO; Mohammad F. Ali, MD Kamel Abou…...

2+ day, 16+ hour ago   (353+ words) Adding atezolizumab to neoadjuvant chemotherapy did not significantly improve EFS in early TNBC, but node-positive and high-TIL subgroups showed benefit. The addition of atezolizumab to sequential taxane, carboplatin, and anthracycline-based neoadjuvant chemotherapy did not significantly improve event-free survival (EFS) in…...

2+ day, 21+ hour ago   (207+ words) Aditya Bardia, MD, MPH, FASCO; Priya Kumar, MBBS, MS Aditya Bardia, MD, MPH, FASCO; Mohammad F. Ali, MD Jonathan Goldman, MD; Sanja Dacic, MD, PhD; Deborah Doroshow, MD, PhD; Anne S. Tsao, MD, MBA Kamel Abou Hussein, MD; Kate Baxstrom, MD Geoffrey…...

2+ day, 21+ hour ago   (207+ words) Aditya Bardia, MD, MPH, FASCO; Priya Kumar, MBBS, MS Aditya Bardia, MD, MPH, FASCO; Mohammad F. Ali, MD Jonathan Goldman, MD; Sanja Dacic, MD, PhD; Deborah Doroshow, MD, PhD; Anne S. Tsao, MD, MBA Kamel Abou Hussein, MD; Kate Baxstrom, MD Geoffrey…...

3+ day, 4+ hour ago   (282+ words) Josef Vymazal, MD, explained why high-relaxivity contrast agents are critical for detecting small brain metastases, despite weaker agents remaining suitable for other indications. Vymazal noted that gadopiclenol’s potency allows it to be approved at half the dose typically used for…...

3+ day, 21+ hour ago   (642+ words) The interim 3-year OS rates were 71.2% with OST-HER2 vs 45.8% in historical controls in a phase 2b trial of fully resected, pulmonary metastatic osteosarcoma. Treatment with OST-HER2 (OST31-164) produced a statistically significant improvement in 3-year overall survival (OS) compared with a combined published…...

3+ day, 17+ hour ago   (369+ words) The FDA has granted accelerated approval to sevabertinib for metastatic non-squamous NSCLC with HER2 TKD activating mutations based on results from the SOHO-01 trial. The FDA has granted accelerated approval to sevabertinib (Hyrnuo) as a treatment for those with locally advanced…...

6+ day, 17+ hour ago   (260+ words) Lisa Cassileth, MD, FACS, discussed why she investigated whether upsizing breast implants increased mastectomy flap necrosis risk. Cassileth LB, Killeen KL, York A, Rosen D. Does breast implant size larger than mastectomy specimen size increase the risk of flap necrosis? Aesthet…...

1+ week, 1+ day ago   (279+ words) FDA approved camizestrant for HR+/HER2– advanced breast cancer with emerging ESR1 mutations based on data from the SERENA-6 trial. The FDA has approved camizestrant (Etcamah) for adult patients with hormone receptor (HR)–positive, HER2-negative locally advanced or metastatic breast cancer with…...

1+ week, 3+ day ago   (404+ words) The European Commission has approved T-DXd plus pertuzumab as first-line therapy for HER2-positive metastatic breast cancer based on DESTINY-Breast09. The approval follows a positive opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency and…...